3 Contract Research Partner, Specialty Formulations and Branded Generics Stocks With a Strong Future Roadmap: Sai Life Sciences, Rubicon Research and Ajanta Pharma

Specialty pharma and research services stocks let investors follow companies that develop and sell higher-value medicines. Sai Life Sciences, Rubicon Research and Ajanta Pharma cover contract research and manufacturing, specialty formulations and branded generics in emerging markets.

This list covers three specialty pharma and research services stocks with complete current figures: Sai Life Sciences, Rubicon Research and Ajanta Pharma. Every figure comes from the latest reported financials and the 21 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Specialty Pharma and Research Services Stocks?

Specialty pharma and research services stocks are listed companies that work on drug development for others or sell differentiated formulations and branded generics. Their earnings depend on programme wins, approvals and brand strength.

Specialty Pharma and Research Services Stocks at a Glance

On valuation, all three trade at a P/E above their industry P/E, which reflects the growth the market already expects from them. Readers comparing specialty pharma and research services stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in specialty pharma and research services stocks can use the coming numbers to test whether growth is holding.

Why Do Specialty Pharma and Research Services Stocks Have a Strong Roadmap in India?

Specialty pharma and research services stocks have a strong roadmap in India because global drug developers are outsourcing more research work and customers prefer differentiated products over basic generics.

• Outsourced research. Drug developers share discovery and development work with Indian partners.
• Differentiated products. Specialty formulations earn better pricing than basic generics.
• Emerging markets. Branded generics build repeat demand in Asia and Africa.

Why Sai Life Sciences Features Among These Specialty Pharma and Research Services Stocks

Among the specialty pharma and research services stocks on this list, Sai Life Sciences is a Hyderabad-based contract research, development and manufacturing organisation that works with global pharma and biotech companies from discovery through commercial supply.

Revenue rose from Rs 898 crore in FY22 to Rs 2,242 crore in FY26, a compound annual growth rate of 25.7%. Net profit grew from Rs 170 crore in FY25 to Rs 349 crore in FY26, a rise of 105.1%.

In the June 2026 quarter, revenue grew 10.2% year on year to Rs 558 crore, while net profit rose 21.2% to Rs 73.3 crore. The company has a return on equity of 14.1%, a debt to equity ratio of 0.12 and a market capitalisation of Rs 29,679 crore. The stock trades at a P/E of 82.0, above the industry P/E of 36.0.

Roadmap: The roadmap is built on adding development and manufacturing capacity and moving more projects from discovery into late-stage and commercial supply. Customers tend to stay with a partner across the drug life cycle, which creates a durable order pipeline.

What to watch: Monitor project conversion from development to commercial stages and customer concentration.

Why Rubicon Research Features Among These Specialty Pharma and Research Services Stocks

Among the contract research shares on this list, Rubicon Research is a pharmaceutical formulations company that develops and sells specialty and complex generic products, with the United States as its main market.

In the June 2026 quarter, revenue grew 52.9% year on year to Rs 540 crore, while net profit rose 95.8% to Rs 84.8 crore. Revenue rose from Rs 330 crore in FY22 to Rs 1,762 crore in FY26, a compound annual growth rate of 52.0%.

Net profit grew from Rs 91.0 crore in FY24 to Rs 247 crore in FY26, which works out to a compound annual growth rate of 64.7%. The company has a return on equity of 19.1%, a debt to equity ratio of 0.24 and a market capitalisation of Rs 24,654 crore. The stock trades at a P/E of 85.5, above the industry P/E of 36.0.

Roadmap: The company builds differentiated products that need technical skill and earn better pricing than basic generics. A growing list of approved products and an own-label model give it room to widen its portfolio.

What to watch: Follow new product approvals and launches in the United States.

Why Ajanta Pharma Features Among These Specialty Pharma and Research Services Stocks

Among the three companies on this list, Ajanta Pharma is a specialty pharmaceutical company that sells branded generics in India and in emerging markets across Asia and Africa, with a focus on ophthalmology, dermatology, cardiology and pain management, and also sells generics in the United States.

The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0.

Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore.

Roadmap: The company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.

What to watch: Monitor the pace of new launches in branded markets and the recovery trends in the United States generics business.

Sai Life Sciences vs Rubicon Research vs Ajanta Pharma on Key Financials

The table below sets the three specialty pharma and research services stocks side by side on revenue, profit and margin, using reported figures.

Ajanta Pharma posts the highest return on equity in this group at 23.3%. Ajanta Pharma has the largest FY26 revenue at Rs 5,625 crore, and Rubicon Research shows the fastest revenue growth with a 52.0% compound annual rate. A useful habit with specialty pharma and research services stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several branded generic stocks instead of one name, which keeps a single result from deciding the outcome.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Specialty Pharma and Research Services Stocks

Every theme carries risks that deserve a check before any decision. For these specialty pharma and research services stocks, the main points are: Long-term contract research shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Programme timing. Research revenue depends on the pace of customer projects.
• Approval timelines. Launches depend on regulatory decisions that can shift.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter specialty pharma and research services stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Specialty Pharma and Research Services Stocks

Specialty pharma and research services stocks reward investors who follow customer programmes, approvals and brand growth together. Sai Life Sciences, Rubicon Research and Ajanta Pharma each target higher-value segments. Based on the 21 October 2026 close, Sai Life Sciences trades at Rs 1,393.6, Rubicon Research at Rs 1,448.5 and Ajanta Pharma at Rs 3,260.2. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these specialty pharma and research services stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track specialty pharma and research services stocks, set price alerts and get research-backed stock ideas.

What are specialty pharma and research services stocks?

Ans. Specialty pharma and research services stocks are listed companies that work on drug development for others or sell differentiated formulations and branded generics. Their earnings depend on programme wins, approvals and brand strength. This list looks at three of them, Sai Life Sciences, Rubicon Research and Ajanta Pharma, using reported FY22 to FY26 financials and the 21 October 2026 closing prices.

Which specialty pharma and research services stocks are covered in this list?

Ans. This list covers Sai Life Sciences, Rubicon Research and Ajanta Pharma. Based on the 21 October 2026 close, Sai Life Sciences traded at Rs 1,393.6, Rubicon Research at Rs 1,448.5 and Ajanta Pharma at Rs 3,260.2. Their return on equity ranges from 14.1% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.9% to 52.0%.

Why do specialty pharma and research services stocks have a strong future roadmap in India?

Ans. Specialty pharma and research services stocks have a strong roadmap in India because global drug developers are outsourcing more research work and customers prefer differentiated products over basic generics. The main drivers are as follows. Outsourced research. Drug developers share discovery and development work with Indian partners. Differentiated products. Specialty formulations earn better pricing than basic generics. Emerging markets. Branded generics build repeat demand in Asia and Africa. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Sai Life Sciences performed financially?

Ans. Revenue rose from Rs 898 crore in FY22 to Rs 2,242 crore in FY26, a compound annual growth rate of 25.7%. Net profit grew from Rs 170 crore in FY25 to Rs 349 crore in FY26, a rise of 105.1%. In the June 2026 quarter, revenue grew 10.2% year on year to Rs 558 crore, while net profit rose 21.2% to Rs 73.3 crore. The company has a return on equity of 14.1%, a debt to equity ratio of 0.12 and a market capitalisation of Rs 29,679 crore. The stock trades at a P/E of 82.0, above the industry P/E of 36.0. Looking ahead, the roadmap is built on adding development and manufacturing capacity and moving more projects from discovery into late-stage and commercial supply. Customers tend to stay with a partner across the drug life cycle, which creates a durable order pipeline.

How has Rubicon Research performed financially?

Ans. Revenue rose from Rs 330 crore in FY22 to Rs 1,762 crore in FY26, a compound annual growth rate of 52.0%. Net profit grew from Rs 91.0 crore in FY24 to Rs 247 crore in FY26, which works out to a compound annual growth rate of 64.7%. In the June 2026 quarter, revenue grew 52.9% year on year to Rs 540 crore, while net profit rose 95.8% to Rs 84.8 crore. The company has a return on equity of 19.1%, a debt to equity ratio of 0.24 and a market capitalisation of Rs 24,654 crore. The stock trades at a P/E of 85.5, above the industry P/E of 36.0. Looking ahead, the company builds differentiated products that need technical skill and earn better pricing than basic generics. A growing list of approved products and an own-label model give it room to widen its portfolio.

How has Ajanta Pharma performed financially?

Ans. Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0. Looking ahead, the company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.

What risks should investors check before buying specialty pharma and research services stocks?

Ans. Investors should check a few risks before buying specialty pharma and research services stocks. Programme timing. Research revenue depends on the pace of customer projects. Approval timelines. Launches depend on regulatory decisions that can shift. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of specialty pharma and research services stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 21 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.